Collaboration and License Agreements (Tables)

9 Months Ended

Jun. 30, 2023

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Summary of Revenue

The following table provides a summary of revenue recognized:

	Three Months Ended June 30,				Nine Months Ended June 30,
	2023		2022		2023		2022
	(in thousands)
GSK	$	277	$	—	$	29,600	$	120,000
Horizon	1,539		6,666		23,206		21,251
Takeda	14,009		25,507		146,477		67,100
Janssen	—		239		355		3,305
Amgen	—		—		25,000		—
Total	$	15,825	$	32,412	$	224,638	$	211,656

Schedule of Receivables and Contract Liabilities

The following table summarizes the balance of receivables and contract liabilities related to the Company’s

collaboration and license agreements:

	June 30, 2023		September 30, 2022
	(in thousands)
Receivables included in accounts receivable	$	1,539	$	6,174
Contract liabilities included in deferred revenue	$	16,905	$	130,049